American Society of Hematology

Jan32025 by adminNo Comments

AZD0486 Shows Good Efficacy in Relapsed/Refractory Follicular Lymphoma

Meeting Coverage > > ASH Expert Roundtable: Follicular Lymphoma-- Novel CD19xCD3 T-cell engager revealed high reaction rate in stage I research study by Greg Laub, Director, Video, MedPage Today January 2, 2025 At the current American Society of Hematology (ASH) yearly conference, information from a stage I trial of AZD0486-- an unique CD19xCD3 bispecific T-cell engager-- revealed high reaction rates and motivating security in relapsed/refractory follicular lymphoma clients, highlighting its possible function in sequencing methods. In this 3rd of 4 unique episodes, MedPage Today combined 3 professional leaders in the field, a...

Incorporating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation

Health and Mediacal

Meeting Coverage > > ASH Expert Roundtable: Multiple Myeloma-- Experts weigh the function of MRD in customizing treatment however care versus early modifications by Greg Laub, Director, Video, MedPage Today December 28, 2024 At the American Society of Hematology yearly conference, a roundtable conversation highlighted the progressing function of very little recurring illness (MRD) as a treatment endpoint in several myeloma, exploring its ramifications for treatment escalation, de-escalation, and discontinuation. MedPage Today united 3 skilled leaders in the field: Moderator Joseph Mikhael, MD, is signed up with by Amrita Krish...

Infection Main Cause of Nonrelapse Death With CAR T Therapy

Health and Mediacal

SAN DIEGO-- Infections represent almost half of all deaths not triggered by illness regression amongst clients with innovative blood cancers after treatment with chimeric antigen receptor (CAR) T-cell treatment, a brand-new meta-analysis of medical trials and real-world research studies programs.The research study, which examined nonrelapse death amongst 7246 clients after treatment with any of the 6 presently authorized CAR T-cell treatments, revealed that infections represented 48.7% of all nonrelapse deaths, although the pathogen was defined in just one third of cases with infection noted as the cause of death, reported David Cordas dos Santos, MD, at the American Society of Hematology (ASH) yearly conference."Our findings highlight the value of post-CAR-T infections, and the requiremen...